Search

Your search keyword '"Dermatologic agents -- Product development"' showing total 87 results
Start Over Descriptor "Dermatologic agents -- Product development" Publication Year Range Last 3 years
87 results on '"Dermatologic agents -- Product development"'

1. Alumis announces OLE data from phase 2 STRIDE clinical trial of ESK-001 to treat psoriasis

Subjects
Psoriasis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Alumis Inc, a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, announced positive [...]

Published
2024

2. Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Alumis Inc. a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated [...]

Published
2024

3. Announcement that the company has developed a new Chinese medicine AC-203 for the treatment of simple hereditary epidermolytic blistering syndrome (EBS), and has obtained approval from the Australian TGA (Therapeutic Goods Administration) to conduct Phase II/III human clinical trials

Subjects
Skin diseases -- Health aspects, Medicine, Oriental -- Health aspects, Dermatology -- Formulae, receipts, prescriptions, Drug approval -- Health aspects, Clinical trials -- Health aspects, Dermatologic agents -- Product development
Abstract

TWi Biotechnology, Inc. has announced the development of a new drug, AC-203, for the treatment of Epidermolysis Bullosa Simplex (EBS). The drug has received approval from the Therapeutic Goods Administration [...]

Published
2023

4. The company's new drug AC-203, developed for the treatment of hereditary epidermolytic blistering syndrome (EBS), has officially submitted an application to the Australian TGA (Therapeutic Goods Administration) for Phase II/III human clinical trials

Subjects
Skin diseases -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Drug approval -- Health aspects, Clinical trials -- Health aspects, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development
Abstract

Ancheng Biotechnology has applied to the Australian TGA to conduct Phase II/III human clinical trials of AC-203, a new drug used to treat simple hereditary epidermolytic blistering syndrome (EBS). AC-203 [...]

Published
2023

5. Research on Eczema Published by a Researcher at University of Bristol (Capturing and reporting topical treatment use in childhood eczema: lessons for data collection in eczema trials)

Subjects
Eczema -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Data entry, Clinical trials, Dermatologic agents -- Product development, Health, University of Bristol
Abstract

2024 SEP 6 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in eczema. According to news reporting out of Bristol, [...]

Published
2024

6. Huaotai HB0017 (IL-17A monoclonal antibody) injection for treatment of plaque psoriasis successfully completed the enrollment of patients in the key Phase III clinical trial

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Interleukins -- Product development, Monoclonal antibodies, Business, Business, international
Abstract

Key Highlight: * Shanghai Huaotai Biopharmaceutical Co., Ltd. announced that the key Phase III clinical trial of its independently developed HB0017 injection successfully completed the enrollment of all subjects on [...]

Published
2024

7. Exosomes Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Subjects
Business -- Research, Clobetasone -- Product development, Dermatology -- Formulae, receipts, prescriptions, Drug approval -- Reports, Clinical trials -- Reports, Dermatologic agents -- Product development, Alitretinoin -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 4, 2024-: Exosomes Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:03072024 DelveInsight, 'Eczema Pipeline Insight 2024' report provides comprehensive insights [...]

Published
2024

8. SFA Therapeutics Announces Completion of Enrollment in Phase 1b Trial of SFA-002 for Psoriasis

Subjects
Psoriasis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business, News, opinion and commentary
Abstract

JENKINTOWN, Pa., May 30, 2024 /PRNewswire/ -- SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small molecule biosynthetic compounds for the treatment of inflammatory diseases, today announced the completion [...]

Published
2024

9. InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Business, Business, international
Abstract

BEIJING -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the [...]

Published
2024

10. InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

BEIJING: INNOCARE PHARMA has issued the following news release: InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced [...]

Published
2024

11. Eczema Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

Subjects
Business -- Research, Clobetasone -- Product development, Eczema, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Clinical trials, Dermatologic agents -- Product development, Alitretinoin -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-May 9, 2024-: Eczema Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) (C)1994-2024 M2 COMMUNICATIONS RDATE:08052024 DelveInsight, 'Eczema Pipeline Insight 2024' report provides comprehensive insights about 100+ [...]

Published
2024

12. InnoCare Pharma begins patient dosing in clinical trial of TYK2 JH2 allosteric inhibitor ICP-488 in China

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Pharmaceuticals and cosmetics industries
Abstract

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the first psoriasis patient has been dosed in clinical trial of the company's TYK2 [...]

Published
2023

13. Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

Subjects
Medical research, Medicine, Experimental, Skin diseases -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Clinical trials, Dermatologic agents -- Product development, Banking, finance and accounting industries, Business
Abstract

Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks [...]

Published
2024

14. Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA[R] (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting

Subjects
Atopic dermatitis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Skin, Dermatologic agents -- Product development, Business, Business, international, Vtama (Medication) -- Product development
Abstract

- Four poster presentations, including two oral presentations, will highlight the clinical data for VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age [...]

Published
2024

15. Plaque Psoriasis Pipeline, Clinical Trials Studies, FDA Approvals, Companies and Latest News 2024 (Updated)

Subjects
Psoriasis -- Reports, Medical research -- Reports, Medicine, Experimental -- Reports, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Adalimumab -- Product development, Clinical trials -- Reports, Dermatologic agents -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-February 6, 2024-: Plaque Psoriasis Pipeline, Clinical Trials Studies, FDA Approvals, Companies and Latest News 2024 (Updated) (C)1994-2024 M2 COMMUNICATIONS RDATE:05022024 DelveInsight's, 'Plaque Psoriasis Pipeline Insight 2024' report provides [...]

Published
2024

16. Delgocitinib Cream Improves Chronic Hand Eczema in Second Phase 3 Trial

Author

Park, Brian

Subjects
Eczema -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Health
Abstract

Positive topline results were announced from a second phase 3 study evaluating delgocitinib cream in adult patients with moderate to severe chronic hand eczema. The phase 3 DELTA 2 study [...]

Published
2023

17. Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Next Generation, Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles

Subjects
Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Physical fitness, Health
Abstract

2022 NOV 5 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Eirion Therapeutics Inc. announced that the first participants have been dosed in [...]

Published
2022

18. Effectiveness and safety of ozone therapy for dermatological disorders: A literature review of clinical trials

Author

Machado, Andressa and Contri, Renata

Subjects
Medical research, Medicine, Experimental, Antioxidants -- Product development, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Air pollution, Health
Abstract

Byline: Andressa. Machado, Renata. Contri Ozone is a strong oxidizing agent, capable of promoting therapeutic effects such as antimicrobial, anti inflammatory, antioxidant and healing activities, with low probability of toxicity [...]

Published
2022

19. Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma

Subjects
Mylan Pharmaceuticals Inc. -- Product development, Bristol-Myers Squibb Co. -- Product development, Psoriasis, Biological products industry -- Product development, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Adalimumab -- Product development, Clinical trials, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, Roflumilast -- Product development, Business, Business, international, Humira (Medication) -- Product development
Abstract

M2 PRESSWIRE-December 5, 2023-: Psoriasis Pipeline, FDA Approvals, Clinical Trials Development, and Companies 2023 | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma (C)1994-2023 M2 COMMUNICATIONS RDATE:04122023 [...]

Published
2023

20. Psoriasis Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Therapeutic Analysis | Amgen, AbbVie, Alumis, DICE Therapeutics, UCB Pharma, Janssen

Subjects
United States. Food and Drug Administration -- Reports, Sun Pharmaceutical Industries Ltd. -- Product development, Psoriasis -- Drug therapy, Medical research -- Health aspects -- Reports, Medicine, Experimental -- Health aspects -- Reports, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Clinical trials -- Health aspects -- Reports, Dermatologic agents -- Product development, Roflumilast -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-December 4, 2023-: Psoriasis Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Therapeutic Analysis | Amgen, AbbVie, Alumis, DICE Therapeutics, UCB Pharma, Janssen [...]

Published
2023

21. Exploring the Plaque Psoriasis Pipeline 2023: Recent FDA, EMA, and PMDA Approvals, Innovative Therapies, Ongoing Clinical Trials, and Treatment Perspectives by Bio-Thera Solutions, Jiangsu HengRui

Subjects
Psoriasis -- Drug therapy, Medical research -- Reports, Medicine, Experimental -- Reports, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Clinical trials -- Reports, Dermatologic agents -- Product development, Roflumilast -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-November 23, 2023-: Exploring the Plaque Psoriasis Pipeline 2023: Recent FDA, EMA, and PMDA Approvals, Innovative Therapies, Ongoing Clinical Trials, and Treatment Perspectives by Bio-Thera Solutions, Jiangsu HengRui (C)1994-2023 [...]

Published
2023

22. Psoriasis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Mylan, Biocad, Celltrion, Coherus, Janssen, Can-Fite Biopharma

Subjects
Psoriasis -- Drug therapy, Biological products industry -- Product development -- Forecasts and trends, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Clinical trials -- Forecasts and trends -- Reports, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development -- Forecasts and trends, Roflumilast -- Product development, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-November 15, 2023-: Psoriasis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Mylan, Biocad, Celltrion, Coherus, Janssen, Can-Fite Biopharma (C)1994-2023 M2 [...]

Published
2023

23. Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Subjects
Dermatology -- Formulae, receipts, prescriptions, Skin -- Care and treatment, Cancer -- Care and treatment, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

MARLBOROUGH: Phio Pharmaceuticals Corp. has issued the following press release: Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYLtm RNAi platform technology is designed to make [...]

Published
2023

24. Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Subjects
T cells, Dermatology -- Formulae, receipts, prescriptions, Skin -- Care and treatment, Cancer -- Care and treatment, Clinical trials, Dermatologic agents -- Product development, Banking, finance and accounting industries, Business
Abstract

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL(TM) RNAi platform technology is designed to make immune cells [...]

Published
2023

25. MC2 Therapeutics begins patient dosing in European phase 2 trial in CKD-aP

Subjects
Skin diseases -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Skin, Dermatologic agents -- Product development, Kidney diseases -- Care and treatment, Pharmaceuticals and cosmetics industries
Abstract

MC2 Therapeutics A/S, a commercial stage pharmaceutical company, announces that the first patients have been dosed in its European phase 2 trial, MC2-25-C1, evaluating the safety and efficacy of MC2-25 [...]

Published
2022

26. Can-Fite BioPharma selected to present psoriasis Phase III data

Subjects
Psoriasis -- Analysis, Biological products industry -- Product development, Medical research -- Analysis, Medicine, Experimental -- Analysis, Dermatology -- Formulae, receipts, prescriptions, Clinical trials -- Analysis, Dermatologic agents -- Product development, Business, News, opinion and commentary
Abstract

Can-Fite BioPharma announced today that Dr. Kim Papp, MD, PhD, will present late-breaking news at the 31st European Academy of Dermatology and Venerology, EADV, Congress from an ongoing analysis of [...]

Published
2022

27. Arcutis Biotherapeutics: FDA approves NDA for ZORYVE cream 0.3%

Subjects
United States. Food and Drug Administration, Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Drug approval, Dermatologic agents -- Product development, Business, News, opinion and commentary
Abstract

Arcutis Biotherapeutics announced that the U.S. FDA has approved the New Drug Application for ZORYVE cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years [...]

Published
2022

28. Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited

Subjects
Psoriasis -- Care and treatment, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, Physical fitness, Industry hiring, Health
Abstract

2022 JUN 4 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that half [...]

Published
2022

29. Reports from Dermatology Service Advance Knowledge in Clinical Trial Research (Evaluation of Curcumin for Dermatologic Conditions: a Systematic Review)

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Skin diseases -- Reports, Dermatology -- Formulae, receipts, prescriptions, Clinical trials -- Reports, Dermatologic agents -- Product development, Evidence-based medicine -- Reports, Health
Abstract

2024 JAN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on Clinical Trial Research is now available. According to news [...]

Published
2024

30. Hidradenitis Suppurativa Market Spotlight Report 2021 - ResearchAndMarkets.com

Subjects
Skin diseases -- Diagnosis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Pharmaceutical industry -- Industry forecasts, Health
Abstract

2022 FEB 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- The 'Market Spotlight: Hidradenitis Suppurativa' report has been added to ResearchAndMarkets.com's offering. [...]

Published
2022

31. Plaque Psoriasis Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., and others

Subjects
Psoriasis -- Reports, Biological products industry -- Product development, Business -- Research, Medical research -- Reports, Medicine, Experimental -- Reports, Alefacept -- Reports, Dermatology -- Formulae, receipts, prescriptions, Clinical trials -- Reports, Adalimumab -- Product development, Dermatologic agents -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 17, 2023-: Plaque Psoriasis Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., and others (C)1994-2023 M2 [...]

Published
2023

32. InnoCare Reports First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

Subjects
Psoriasis -- Drug therapy, Medical research, Medicine, Experimental, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

BEIJING: InnoCare Pharma , a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced the first psoriasis patient has been dosed in clinical trial of the [...]

Published
2023

33. Psoriasis Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs (2023) | Companies - Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen, Can-Fite Biopharma

Subjects
Bristol-Myers Squibb Co. -- Forecasts and trends -- Product development, Psoriasis -- Forecasts and trends -- Reports, Biological products industry -- Product development -- Forecasts and trends, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Clinical trials -- Forecasts and trends -- Reports, Adalimumab -- Product development, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development -- Forecasts and trends, Roflumilast -- Product development, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-June 22, 2023-: Psoriasis Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs (2023) | Companies - Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen, Can-Fite Biopharma. (C)1994-2023 M2 COMMUNICATIONS [...]

Published
2023

34. Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

Subjects
Dr. Reddy's Laboratories Ltd. -- Product development, Medical research, Medicine, Experimental, Skin diseases -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Minocycline -- Product development, Clinical trials, Drug approval, Dermatologic agents -- Product development, Adults, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Oracea (Medication) -- Product development
Abstract

SCOTTSDALE: Journey Medical Corporation has issued the following press release: Journey Medical Corporation (Nasdaq: DERM) ('Journey Medical'), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of [...]

Published
2023

35. Complicated Skin And Soft Tissue Infections Clinical Trials | A Drug Pipeline Analysis Report 2023 Companies - Stempeutics, Angiocrine Bioscience, Carephar

Subjects
Business -- Research, Biotechnology industry -- Product development, Dermatology -- Formulae, receipts, prescriptions, Infection -- Health aspects, Clinical trials -- Health aspects, Skin -- Health aspects, Dermatologic agents -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 8, 2023-: Complicated Skin And Soft Tissue Infections Clinical Trials | A Drug Pipeline Analysis Report 2023 Companies - Stempeutics, Angiocrine Bioscience, Carephar (C)1994-2023 M2 COMMUNICATIONS RDATE:07062023 'DelveInsight [...]

Published
2023

36. Sareum doses first subjects in psoriasis drug trial

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Business, international
Abstract

London: Sareum Holdings PLC has issued the following press release: Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of [...]

Published
2023

37. Supply Of Mft Drug (ph No.:49067) Liquid Paraffin + Soft Paraffin (emollient Cream) Mft Drug (ph No.:49067) Liquid Paraffin + Soft Paraffin (emollient Cream)

Subjects
Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Business, international
Abstract

Tenders are invited for Supply of mft drug (ph no.:49067) liquid paraffin + soft paraffin (emollient cream) mft drug (ph no.:49067) liquid paraffin + soft paraffin (emollient cream) Tender Category [...]

Published
2023

38. Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Subjects
United States. Food and Drug Administration -- Planning, T cells, Dermatology -- Formulae, receipts, prescriptions, Cancer -- Care and treatment, Clinical trials, Skin, Dermatologic agents -- Product development, Company business planning, Business, News, opinion and commentary
Abstract

MARLBOROUGH, Mass., May 16, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL[sup.(TM)] RNAi platform technology is designed to make immune cells more [...]

Published
2023

39. Sareum receives Australian approval for psoriasis drug clinical trial

Subjects
Psoriasis -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Drug approval, Dermatologic agents -- Product development, Business, international
Abstract

London: Sareum Holdings PLC has issued the following press release: Sareum Holdings PLC on Friday said its application to start a phase 1 clinical trial in Australia of its lead [...]

Published
2023

40. University of Texas Southwestern Medical Center Researchers Have Published New Data on Psoriasis (Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials)

Subjects
United States. Food and Drug Administration -- Reports, Psoriasis -- Patient outcomes -- Drug therapy, Medical centers -- Reports, Atopic dermatitis -- Patient outcomes -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Photography -- Reports, Clinical trials -- Reports, Drug approval -- Reports, Dermatologic agents -- Product development, Health
Abstract

2023 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A new study on psoriasis is now available. According to news originating from [...]

Published
2023

41. Supply Of Mft Drug (ph No.:49067) Liquid Paraffin + Soft Paraffin (emollient Cream) Mft Drug (ph No.:49067) Liquid Paraffin + Soft Paraffin (emollient Cream)

Subjects
Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Business, international
Abstract

Tenders are invited for Supply of mft drug (ph no.:49067) liquid paraffin + soft paraffin (emollient cream) mft drug (ph no.:49067) liquid paraffin + soft paraffin (emollient cream) Tender Category [...]

Published
2023

42. Propulsion of Psoriasis Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Treatment Domain | Major Companies - Bristol-Myers Squibb, Amgen, GSK, and Others

Subjects
Bristol-Myers Squibb Co. -- Forecasts and trends -- Product development, Psoriasis -- Forecasts and trends -- Reports, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Adalimumab -- Product development, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development -- Forecasts and trends, Roflumilast -- Product development, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-April 19, 2023-: Propulsion of Psoriasis Pipeline as Novel and Extensive 80+ Therapies Likely to Enter in the Treatment Domain | Major Companies - Bristol-Myers Squibb, Amgen, GSK, and [...]

Published
2023

43. Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Subjects
Dr. Reddy's Laboratories Ltd. -- Product development, Medical research, Medicine, Experimental, Skin diseases, Dermatology -- Formulae, receipts, prescriptions, Minocycline -- Product development, Clinical trials, Dermatologic agents -- Product development, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

SCOTTSDALE, Ariz: Journey Medical Corporation has issued the following news release: Journey Medical Corporation (Nasdaq: DERM) ('Journey Medical'), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of [...]

Published
2023

44. Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Subjects
Medical research, Medicine, Experimental, Skin diseases, Dermatology -- Formulae, receipts, prescriptions, Minocycline -- Product development, Clinical trials, Dermatologic agents -- Product development, Banking, finance and accounting industries, Business
Abstract

Subjects completed 16-week treatment with no significant safety issues Topline results expected in the first half of 2023 SCOTTSDALE, Ariz., March 16, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: [...]

Published
2023

45. Roivant surges 7% premarket as skin cream Vtama meets main goal of phase 3 eczema trial

Subjects
Atopic dermatitis, Toiletries industry -- Product development, Dermatology -- Formulae, receipts, prescriptions, Eczema, Skin, Dermatologic agents -- Product development, General interest, News, opinion and commentary, Vtama (Medication) -- Product development
Abstract

Dermavant Sciences' Vtama cream met the primary objective of clearer skin in a Phase 3 study in two-year-old and adult patients with atopic dermatitis (AD). Vtama is already approved in [...]

Published
2023

46. Supply Of Mft Drug (ph No.:49067) Liquid Paraffin + Soft Paraffin (emollient Cream)

Subjects
Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Business, international
Abstract

Tenders are invited for Supply of Mft drug (ph no.:49067) liquid paraffin + soft paraffin (emollient cream) Tender Category : Goods OpeningDate : Apr 10 2023 10:30AM Major organization : [...]

Published
2023

47. Rosacea Marketed and Emerging Pipeline Drugs Assessment, 2023 | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Subjects
Sol-Gel Technologies -- Product development, Business -- Research, Dermatology -- Formulae, receipts, prescriptions, Dermatologic agents -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-March 7, 2023-: Rosacea Marketed and Emerging Pipeline Drugs Assessment, 2023 | Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies [...]

Published
2023

48. Eczema Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

Subjects
Dermatology -- Formulae, receipts, prescriptions, Eczema -- Forecasts and trends, Dermatologic agents -- Product development, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-February 21, 2023-: Eczema Pipeline Analysis Demonstrates Novel 100+ Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight (C)1994-2023 M2 COMMUNICATIONS RDATE:20022023 DelveInsight's, 'Eczema Pipeline Insight, [...]

Published
2023

49. 80+ Leading Psoriasis Pipeline Companies are working to improve the Treatment Landscape

Subjects
Psoriasis -- Forecasts and trends -- Reports, Dermatology -- Formulae, receipts, prescriptions, Adalimumab -- Product development, Dermatologic agents -- Product development, Roflumilast -- Product development, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-February 9, 2023-: 80+ Leading Psoriasis Pipeline Companies are working to improve the Treatment Landscape (C)1994-2023 M2 COMMUNICATIONS RDATE:08022023 DelveInsight's, 'Psoriasis Pipeline Insight, 2023,' report provides comprehensive insights about [...]

Published
2023

50. New drug treatment for eczema is 'highly effective' trials show; It has already been approved in the US and should now be made available in the UK

Subjects
Medical research, Medicine, Experimental, Eczema -- Drug therapy, Dermatology -- Formulae, receipts, prescriptions, Clinical trials, Dermatologic agents -- Product development, General interest, News, opinion and commentary
Abstract

Byline: By, Neil Shaw A new drug therapy to treat moderate to severe eczema in young children has been shown to be 'safe and highly effective' in clinical trials. In [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results